Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Specialties
Hematology
Oncology
Musculoskeletal Disorder
Rare Disease
Metabolic Disorder
Cardiovascular Disease
Ophthalmology
Neurology
Infectious Disease
View all Specialties
Technologies
Cell Therapy
MSC
iPSC
Gene Therapy
Genome Editing
Extracellular Vesicles
CAR-T Therapy
TCR Therapy
Tissue-Engineering & Biomaterials
View all Technologies
Topics
Treatment
Immuno-Oncology
Trial Updates
Perspectives
Manufacturing
COVID-19
View all Topics
Conferences
ASH 2022
TCT 2022
Meeting on the Med 2022
ICLE 2022
Advanced Therapies Week 2022
TERMIS 2021
ESGCT 2021
Meeting on the Mesa 2021
Advanced Therapies 2021
View all Conferences
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Speciality: Hematology
5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein
• 9 Dec 2022
1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam
• 12 Dec 2022
2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman
• 11 Dec 2022
2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman
• 11 Dec 2022
3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda
• 11 Dec 2022
2:45
Phase I study of CC-98633 in R/R multiple myeloma
Luciano Costa
• 11 Dec 2022
1:00
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma
Mazyar Shadman
• 9 Dec 2022
8:17
CART19-BE-01: ARI-0001 in CD19+ malignancies
Valentín Ortiz-Maldonado
• 11 Oct 2020
1:58
Cellular therapies: from academia to industry
Jürgen Kuball
• 1 Sep 2020
5:03
Meta-analysis: anti-BCMA CAR-T in R/R myeloma
Nico Gagelmann
• 1 Sep 2020
3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault
• 1 Sep 2020
1:45
Challenges associated with CAR T-cell production
Valentín Ortiz-Maldonado
• 1 Sep 2020
5:43
Gene editing: legal and ethical considerations
Aurélie Mahalatchimy
• 1 Sep 2020
1:35
Gamma delta T-cell therapy
Jürgen Kuball
• 1 Sep 2020
3:39
Future of anti-BCMA CAR T-cell therapy in myeloma
Noopur Raje
• 1 Sep 2020
2:40
The potential of gene-edited effector cell therapy
Maksim Mamonkin
• 1 Sep 2020
1
2
Next